Malaria Clinical Trial
Official title:
Clinical Evaluation of Combined Use of ITN's and Plant-based Insect Repellent Against Malaria in the Amazon
Insecticide Treated Nets (ITN's) offer good protection against malaria in Africa where the vector mosquitoes feed indoors late at night. However, in other parts of the world like South America, vectors feed earlier in the evening before people go to bed. In such cases it may be necessary to use alternative treatments in the evening to supplement the efficacy of ITN's. This study compares 2 matched groups of households in the Bolivian Amazon. One group will be given ITN's plus a plant-based insect repellent in the evening, the other has ITN's plus a placebo lotion. Households are monitored over a full malaria season to record numbers of malaria cases.
There is little doubt that the use of insecticide treated bed nets (ITN's) is one of the
most successful means of reducing malaria in Africa. However, vectors in this region tend to
be late night, indoor feeders. Vector species in other parts of the world may not be so
susceptible to this form of vector control. In much of Central & Southern America, the major
vectors such as An. darlingi and An. albitarsis have a feeding peak between 8 - 10pm, before
most people retire to bed. Similarly, the major vector in much of S.E. Asia, An. dirus,
seldom enters homes to feed. In these circumstances it is unlikely ITN's alone will provide
adequate protection. Supplemental use of skin applied insect repellents may be an effective
method of personal protection in the hours between dusk and retiring to bed. It would also
prove useful for those individuals working late or moving early into the forest where
exophagic species are encountered. As yet, there have been no robust clinical evaluations of
combined ITN and repellent use. This double blind, placebo-controlled study is designed to
evaluate the efficacy of combined ITN and plant based insect repellent use to reduce P.
falciparum in the Bolivian Amazon in a region where ITN's alone are likely to be
ineffective.
The study is a double-blind, placebo-controlled clinical evaluation. 1000 households will be
used and 5 individuals age 10 + will be entered into the study from each. Recruitment will
cover all rural communities in Vaca Diez and Pando Provinces, Department of Beni in the
Bolivian Amazon Region, plus the outer 10 % of periurban districts of the 2 major towns in
the region, Riberalta and Guayaramerin. A maximum of 20 % of households in any one location
will be used, thus avoiding any effect of diversion of insects from treatment to placebo
homes. Likewise, each house used will be a minimum of 25m from any other in the study.
Baseline surveys will be conducted on each individual and informed written consent will be
collected. Treatment (30 % L.E.) / placebo (0.1 % clove oil in alcohol) marked A or B will
be allocated (50:50) at random, and all individuals in both groups will be provided with an
ITN. Compliance questionnaires, collection of old bottles and distribution of fresh bottles
will be conducted every 4 weeks. Everyone will receive personal instruction on how to apply
repellent to arms & legs each evening at dusk and left a pictorial instruction sheet on how
to measure 10 ml using the bottle lid. Compliance threshold will be set at 10% and monitored
by measuring any residual product on collection and recording of nightly use. A more
realistic measure of compliance will be gained through occasional evening spot checks of
households by the local health workers. Finger prick blood samples will be collected at
baseline and monthly throughout the study by trained & approved field staff. P. falciparum
infection will be diagnosed by Paracheck® dipstick test, thus overcoming problems of
recrudescence of P. vivax. Positive cases will be referred to the local health centre for
treatment. The timing of the visits means the majority of malaria episodes will be detected
as the Paracheck® test can detect antibodies in blood for around 3 weeks post treatment. In
addition to the use of our monthly questionnaires, any episodes missed are highly likely to
be recorded, as we are employing the same local health workers in each area, and blood
slides are routinely taken at the local health centres. Outcome determination will
constitute a series of monthly cross-sectional prevalence surveys, and, as positive cases
are treated, this is equivalent to a measure of average prevalence of infection for each
house.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
| Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
| Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
| Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
| Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
| Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
| Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
| Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
| Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
| Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
| Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
| Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
| Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
| Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
| Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
| Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
| Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
| Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
| Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
| Completed |
NCT02527005 -
A Comparative Study of Azithromycin and S-P as Prophylaxis in Pregnant HIV+ Patients
|
Phase 1 |